Tobias Raum

USPTO Granted Patents = 60 (Patent Applications = 35)

CIPO Patents = 15 (Patent Applications = 10)

EPO Patents = 29 (Patent Applications = 54)

Average Co-Inventor Count = 7.3

ph-index = 13

Forward Citations = 665(Granted Patents)

Forward Citations (Not Self Cited) = 517(Oct 12, 2025)

Location History:

München, DE (2011 - 2014)
Eurasburg, DE (2017 - 2022)
Munich, DE (2007 - 2024)

Company Filing History:

49 out of 75

Amgen Research (munich) Gmbh

Boehringer Ingelheim International Gmbh

Immatics Biotechnologies Gmbh

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

60 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12441796 - Antibody constructs for CDH19 and CD3 (2025-10-14),

2. 12435139 - Antibody constructs for DLL3 and CD3 (2025-10-07),

3. 12428491 - PSMA and CD3 bispecific T cell engaging antibody constructs (2025-09-30),

4. 12312412 - MAGEB2 binding constructs (2025-05-27),

5. 12304952 - Antibody constructs for DLL3 and CD3 (2025-05-20),

6. 12297292 - Antibody constructs for CDH19 and CD3 (2025-05-13),

7. 12281176 - Binding molecules for BCMA and CD3 (2025-04-21),

8. 12281175 - Binding molecules for BCMA and CD3 (2025-04-21),

9. 12281172 - Cross-species-specific PSMAxCD3 bispecific single chain antibody (2025-04-21),

10. 12258411 - Anti-CCR8 antibodies and uses thereof (2025-03-25),

11. 12258404 - Bispecific antibody construct directed to MUC17 and CD3 (2025-03-25),

12. 12152078 - Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3 (2024-11-26),

13. 11987633 - Cross-species-specific single domain bispecific single chain antibody (2024-05-21),

14. 11926666 - Bispecific antibody constructs for CDH3 and CD3 (2024-03-12),

15. 11925684 - Compositions comprising cross-species-specific antibodies and uses thereof (2024-03-12),

Title: Inventor Spotlight: Tobias Raum, Pioneering Innovations in Antibody Technology

Introduction:

Tobias Raum, a distinguished inventor based in Munich, Germany, has made significant contributions to the field of biotechnology with a remarkable portfolio of 48 patents. His groundbreaking work in creating bispecific single chain antibody molecules has revolutionized the landscape of targeted therapeutics.

Latest Patents:

Raum's latest patents include the development of Cross-species-specific single domain bispecific single chain antibody and Bispecific antibody constructs for CDH3 and CD3. The former focuses on a dual-targeting approach to harness the immune system against tumor cells, while the latter aims to enhance T cell-mediated killing of cancer cells through a unique bispecific antibody construct.

Career Highlights:

Throughout his career, Tobias Raum has been associated with reputable companies such as Amgen Research GmbH in Munich and Amgen Inc. These collaborations have provided him with invaluable resources and expertise to drive his innovative research forward, leading to the successful translation of his ideas into tangible patents.

Collaborations:

Raum has had the privilege of working alongside talented individuals such as Peter Kufer and Patrick Hoffmann. Together, they have synergized their knowledge and skills to push the boundaries of antibody engineering and develop novel therapeutic strategies for cancer treatment.

Conclusion:

In conclusion, Tobias Raum stands out as a visionary inventor who has made indelible marks in the realm of antibody technology. His relentless pursuit of innovation, coupled with his collaborative spirit, continues to inspire the biotechnology community and pave the way for transformative advancements in targeted therapeutics.

This text is generated by artificial intelligence and may not be accurate.